 Yubin Miao
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha-MSH | 49 | 2023 | 54 | 17.220 |
Why?
| | Melanoma, Experimental | 29 | 2023 | 118 | 10.540 |
Why?
| | Lactams | 20 | 2023 | 38 | 8.790 |
Why?
| | Radiopharmaceuticals | 21 | 2023 | 187 | 5.840 |
Why?
| | Melanoma | 28 | 2020 | 651 | 5.560 |
Why?
| | Technetium | 14 | 2020 | 22 | 5.010 |
Why?
| | Oligopeptides | 14 | 2018 | 248 | 3.800 |
Why?
| | Tissue Distribution | 37 | 2023 | 324 | 3.720 |
Why?
| | Heterocyclic Compounds, 1-Ring | 17 | 2022 | 20 | 3.650 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 22 | 2023 | 100 | 2.650 |
Why?
| | Kidney | 13 | 2022 | 1207 | 2.310 |
Why?
| | Peptides, Cyclic | 8 | 2020 | 262 | 2.300 |
Why?
| | Receptor, Melanocortin, Type 1 | 15 | 2022 | 23 | 2.270 |
Why?
| | Cell Line, Tumor | 29 | 2023 | 2751 | 2.000 |
Why?
| | Indium Radioisotopes | 11 | 2017 | 24 | 1.970 |
Why?
| | Organotechnetium Compounds | 6 | 2016 | 16 | 1.950 |
Why?
| | Gallium Radioisotopes | 5 | 2020 | 19 | 1.910 |
Why?
| | Mice, Inbred C57BL | 35 | 2023 | 4773 | 1.850 |
Why?
| | Peptides | 10 | 2018 | 864 | 1.730 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2017 | 193 | 1.680 |
Why?
| | Mice | 52 | 2023 | 15052 | 1.620 |
Why?
| | Yttrium Radioisotopes | 6 | 2019 | 57 | 1.390 |
Why?
| | Animals | 59 | 2023 | 32102 | 1.300 |
Why?
| | Peptide Fragments | 7 | 2019 | 675 | 1.300 |
Why?
| | Lutetium | 4 | 2013 | 4 | 1.270 |
Why?
| | Radioisotopes | 5 | 2013 | 34 | 1.160 |
Why?
| | Diagnostic Imaging | 4 | 2018 | 296 | 1.100 |
Why?
| | Molecular Imaging | 2 | 2020 | 52 | 1.070 |
Why?
| | Cyclization | 9 | 2020 | 24 | 0.990 |
Why?
| | Receptors, LHRH | 3 | 2014 | 17 | 0.960 |
Why?
| | Prostatic Neoplasms | 5 | 2018 | 927 | 0.830 |
Why?
| | Rhenium | 5 | 2007 | 9 | 0.820 |
Why?
| | Positron-Emission Tomography | 7 | 2018 | 284 | 0.770 |
Why?
| | Drug Delivery Systems | 5 | 2013 | 301 | 0.760 |
Why?
| | Mice, Nude | 7 | 2018 | 639 | 0.750 |
Why?
| | Lead Radioisotopes | 2 | 2019 | 3 | 0.740 |
Why?
| | Receptors, Peptide | 1 | 2020 | 21 | 0.740 |
Why?
| | Amino Acids | 3 | 2015 | 454 | 0.740 |
Why?
| | Caprylates | 3 | 2014 | 22 | 0.720 |
Why?
| | Acetates | 1 | 2020 | 96 | 0.700 |
Why?
| | Molecular Structure | 7 | 2019 | 447 | 0.690 |
Why?
| | Antineoplastic Agents | 5 | 2013 | 1893 | 0.670 |
Why?
| | Chelating Agents | 7 | 2020 | 71 | 0.620 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 348 | 0.610 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2017 | 11 | 0.600 |
Why?
| | Lung Neoplasms | 4 | 2019 | 2207 | 0.590 |
Why?
| | Coordination Complexes | 2 | 2017 | 13 | 0.580 |
Why?
| | Heme | 4 | 2018 | 56 | 0.570 |
Why?
| | Radionuclide Imaging | 6 | 2014 | 121 | 0.520 |
Why?
| | Amino Acid Sequence | 9 | 2018 | 2000 | 0.510 |
Why?
| | Organometallic Compounds | 5 | 2007 | 102 | 0.480 |
Why?
| | Isotope Labeling | 7 | 2020 | 76 | 0.470 |
Why?
| | Binding, Competitive | 5 | 2018 | 200 | 0.460 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 704 | 0.460 |
Why?
| | Transplantation, Heterologous | 5 | 2017 | 187 | 0.450 |
Why?
| | Phenylalanine | 1 | 2014 | 58 | 0.450 |
Why?
| | Hydrocarbons | 1 | 2013 | 32 | 0.450 |
Why?
| | Breast Neoplasms | 3 | 2014 | 1872 | 0.430 |
Why?
| | Copper | 1 | 2012 | 101 | 0.390 |
Why?
| | Skin Neoplasms | 2 | 2010 | 761 | 0.380 |
Why?
| | Melanocyte-Stimulating Hormones | 1 | 2010 | 3 | 0.370 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 40 | 0.360 |
Why?
| | Indium | 2 | 2008 | 10 | 0.360 |
Why?
| | Structure-Activity Relationship | 6 | 2010 | 511 | 0.350 |
Why?
| | Neoplasm Metastasis | 2 | 2009 | 526 | 0.340 |
Why?
| | Protein Binding | 4 | 2017 | 1917 | 0.330 |
Why?
| | Inhibitory Concentration 50 | 3 | 2014 | 77 | 0.320 |
Why?
| | Biological Transport | 3 | 2020 | 375 | 0.300 |
Why?
| | Neoplasm Transplantation | 5 | 2013 | 235 | 0.290 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2018 | 160 | 0.290 |
Why?
| | Bombesin | 2 | 2018 | 14 | 0.280 |
Why?
| | Drug Design | 3 | 2013 | 156 | 0.260 |
Why?
| | Radiotherapy | 2 | 2005 | 177 | 0.250 |
Why?
| | Heterografts | 2 | 2016 | 119 | 0.240 |
Why?
| | Copper Radioisotopes | 4 | 2014 | 4 | 0.240 |
Why?
| | Integrin alphaVbeta3 | 3 | 2014 | 24 | 0.240 |
Why?
| | Female | 20 | 2015 | 59913 | 0.230 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2017 | 477 | 0.230 |
Why?
| | Humans | 22 | 2020 | 115586 | 0.220 |
Why?
| | Whole Body Imaging | 2 | 2014 | 25 | 0.210 |
Why?
| | Staining and Labeling | 3 | 2013 | 139 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 5 | 2014 | 2392 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2014 | 314 | 0.200 |
Why?
| | Albumins | 1 | 2021 | 91 | 0.190 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2020 | 13 | 0.190 |
Why?
| | Lysine | 2 | 2014 | 245 | 0.180 |
Why?
| | Arginine | 3 | 2015 | 241 | 0.180 |
Why?
| | Flavin Mononucleotide | 1 | 2018 | 8 | 0.160 |
Why?
| | Fluorescence | 1 | 2018 | 154 | 0.150 |
Why?
| | Calmodulin | 1 | 2018 | 72 | 0.150 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2018 | 135 | 0.150 |
Why?
| | Receptors, Bombesin | 2 | 2014 | 4 | 0.150 |
Why?
| | Time Factors | 4 | 2009 | 6165 | 0.150 |
Why?
| | Niacinamide | 1 | 2017 | 65 | 0.150 |
Why?
| | Nitric Oxide Synthase | 1 | 2018 | 213 | 0.150 |
Why?
| | Feasibility Studies | 2 | 2010 | 741 | 0.140 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 397 | 0.130 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 372 | 0.130 |
Why?
| | Tyrosine | 1 | 2016 | 219 | 0.130 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2015 | 26 | 0.130 |
Why?
| | beta-Alanine | 1 | 2014 | 18 | 0.120 |
Why?
| | Dipeptides | 1 | 2014 | 49 | 0.120 |
Why?
| | Aminocaproates | 1 | 2013 | 3 | 0.110 |
Why?
| | Cell Communication | 1 | 2015 | 282 | 0.110 |
Why?
| | Optical Imaging | 1 | 2014 | 55 | 0.110 |
Why?
| | Dimerization | 1 | 2013 | 177 | 0.110 |
Why?
| | Electron Transport | 3 | 2018 | 112 | 0.110 |
Why?
| | Autophagy | 1 | 2015 | 236 | 0.110 |
Why?
| | Survival Analysis | 2 | 2007 | 1219 | 0.110 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 151 | 0.100 |
Why?
| | Heterocyclic Compounds | 2 | 2013 | 20 | 0.100 |
Why?
| | Glycine | 1 | 2012 | 156 | 0.090 |
Why?
| | Indicators and Reagents | 1 | 2011 | 100 | 0.090 |
Why?
| | Sugar Acids | 1 | 2010 | 5 | 0.090 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 153 | 0.090 |
Why?
| | Fatty Acids | 1 | 2013 | 386 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2014 | 691 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2015 | 832 | 0.090 |
Why?
| | Pharmacokinetics | 1 | 2009 | 26 | 0.090 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 576 | 0.090 |
Why?
| | Metabolic Clearance Rate | 2 | 2007 | 108 | 0.080 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 125 | 0.080 |
Why?
| | Melanins | 1 | 2008 | 18 | 0.080 |
Why?
| | Organ Specificity | 2 | 2007 | 273 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2007 | 3580 | 0.080 |
Why?
| | Phantoms, Imaging | 1 | 2008 | 134 | 0.070 |
Why?
| | Streptavidin | 1 | 2007 | 16 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1642 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 495 | 0.070 |
Why?
| | Liver | 1 | 2014 | 1690 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2377 | 0.070 |
Why?
| | Cell Survival | 1 | 2009 | 1024 | 0.070 |
Why?
| | Alpha Particles | 1 | 2005 | 2 | 0.070 |
Why?
| | Bacteriophages | 1 | 2007 | 76 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1178 | 0.060 |
Why?
| | Radiometry | 1 | 2005 | 43 | 0.060 |
Why?
| | Radiation, Ionizing | 1 | 2005 | 73 | 0.060 |
Why?
| | Models, Chemical | 1 | 2007 | 257 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 924 | 0.060 |
Why?
| | Remission Induction | 1 | 2005 | 240 | 0.060 |
Why?
| | Radiography | 1 | 2007 | 826 | 0.060 |
Why?
| | Radiotherapy Dosage | 1 | 2005 | 246 | 0.060 |
Why?
| | Male | 5 | 2018 | 55949 | 0.060 |
Why?
| | Kinetics | 2 | 2018 | 1569 | 0.060 |
Why?
| | Mice, SCID | 1 | 2003 | 321 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2008 | 9159 | 0.050 |
Why?
| | Signal Transduction | 1 | 2015 | 4541 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2800 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2018 | 38 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 178 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 70 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2018 | 267 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 327 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2018 | 346 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2018 | 339 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2018 | 209 | 0.030 |
Why?
| | Deuterium | 1 | 2016 | 78 | 0.030 |
Why?
| | Solvents | 1 | 2016 | 108 | 0.030 |
Why?
| | Lasers | 1 | 2016 | 121 | 0.030 |
Why?
| | Protein Domains | 1 | 2016 | 209 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 515 | 0.030 |
Why?
| | Hydrogen | 1 | 2015 | 62 | 0.030 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2015 | 87 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2015 | 145 | 0.030 |
Why?
| | Protons | 1 | 2015 | 80 | 0.030 |
Why?
| | X-Ray Microtomography | 1 | 2014 | 79 | 0.030 |
Why?
| | Catalytic Domain | 1 | 2015 | 202 | 0.030 |
Why?
| | Catalysis | 1 | 2015 | 299 | 0.030 |
Why?
| | Aminocaproic Acid | 1 | 2013 | 3 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 5 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1390 | 0.030 |
Why?
| | Water | 1 | 2015 | 412 | 0.030 |
Why?
| | Biotinylation | 1 | 2007 | 29 | 0.020 |
Why?
| | Trifluoroacetic Acid | 1 | 2007 | 3 | 0.020 |
Why?
| | Rats | 1 | 2015 | 5034 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2790 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 850 | 0.010 |
Why?
|
|
Miao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|